Pulmonary Adenocarcinoma Patient with Complex Mutations on EGFR Benefits from Furmonertinib after Acquiring Gefitinib Resistance: A Case Report.
Guixian WuQian ChenDongqing LvLing LinJing Huang
Published in: Recent patents on anti-cancer drug discovery (2024)
Pulmonary adenocarcinoma with rare rare complex mutations in EGFR induced by gefitinib resistance and disease progression might benefit from furmonertinib treatment.